维普期刊资源整合服务平台（V6.5）

174篇 您的检索式：作者名="Figg WD"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	The pharmacokinetics of TNP- 470, a new angiogenesis inhibitor 显示文摘	Figg WD Plada JM Lush RM	1997	Pharmacotherapy1997，17，：	1
2	A randomized phase II trim of docetaxel ( taxotere ) plus thalidomide in androgen-independent prostate cancer 显示文摘	Figg WD Aden P Gulley J	2001	Semin Oncol2001，28，415：	1
3	TNP-470:an angiogenesis inhibitor in clinical development for cancer 显示文摘	Kurger EA Figg WD	2000	Expert Opin Investing Drugs2000，9，7：	1
4	A phase Ⅱstudy of Saza-2:deoxycytidine ( Decitabine ) in hormone independent metastatic (D2) prostate cancer显示文摘	Thibault A Figg WD Bergan RC	1998	Tumori1998，84，1：	1
5	Hyporinducibility of hypoxia responsive genes without p53/p212 dependent checkpoint in aggressive prostate cancer 显示文摘	Salnikow K Costa M Figg WD	2000	Cancer Res2000，60，20：	1
6	Phase I clinical trial of oral COL-3,a matrix metalloproteinase inhibitor,in patients with refractory metastatic cancer显示文摘	Rudek MA Figg WD Dyer V	2001	J Clin Oncol2001，19，2：	1
7	Pharmacogenetics of irinotecan metabolism and transport: an update 显示文摘	SMITH NF FIGG WD SPARREBOOM A	2006	Toxicology in Vitro2006，20，2：	1
8	Pharmacogenetics and regulation of human cytochrome P450 1B1:implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention显示文摘	Sissung TM Price DK Sparreboom A Figg WD	2006	Mol Cancer Res2006，4，3：	1
9	Pharmacokinetics of thalidomide in an elderly prostate cancer population 显示文摘	Figg WD	1999	J Pharm Sci1999，88，1：	1
10	Lysyl oxidase (LOX) and hypoxia-induced metastases显示文摘	Sion AM Figg WD	2006	Cancer Biol Ther2006，5，8：	1
11	Hyperinducibility of hypoxia- responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer 显示文摘	Salnikow K Costa M Figg WD	2000	Cancer Res2000，60，20：	1
12	Phase Ⅱ trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade glionuis 显示文摘	Fine HA Figg WD Jaeckle K	2000	Clin 0ncol2000，18，4：	1
13	TNP-470:an angiogenesis inhibitor in clinical development for cancer显示文摘	Kruger EA Figg WD	2000	Expert Opin Investing Drugs2000，9，6：	1
14	Phase I clinical trial of oral COL- 3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer显示文摘	Rudek MA Figg WD Dyer V	2001	J Clin Oncol2001，19，2：	1
15	Angiogenesis inhibitors:current strategies and future prospects显示文摘	Cook KM Figg WD	2010	CA Cancer J Clin2010，60，4：	1
16	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy显示文摘	Sparenboom A Danesi R Ando Y Chan J Figg WD	2003	Drug Resistance Updates2003，6，2：	1
17	A phase Ⅱ study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer显示文摘	Thibault A Figg WD Bergan RC	1998	Tumori1998，84，1：	1
18	Recent advances in pharmacogenetic approaches to antieancer drug development 显示文摘	Smith NF Figg WD Sparreboom A	2004	Drug Development Res2004，62，：	1
19	Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species- dependent显示文摘	Bauer KS Dixon SC Figg WD	1998	Binchem Pharmacol1998，55，11：	1
20	Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia显示文摘	Gore SD Weng LJ Figg WD	2002	Clinical Cancer Research2002，8，4：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示